Publikasi Scopus FKUI Tahun 2010 s/d 2020 (data Per 3 Februari 2021)

Mangunnegoro H., Novariska F., Wiyono W.H., Setiawati A., Louisa M.
6505897768;52564198400;19338014600;7801334843;41461551400;
The efficacy of nebulized procaterol versus nebulized salbutamol for the treatment of moderate acute asthma: A randomized, double-blind, parallel group study
2011
International Journal of Clinical Pharmacology and Therapeutics
49
10
614
621
6
Department of Pulmonology and Respiratory Medicine, University of Indonesia, Persahabatan Hospital, Jakarta, Indonesia; Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia
Mangunnegoro, H., Department of Pulmonology and Respiratory Medicine, University of Indonesia, Persahabatan Hospital, Jakarta, Indonesia; Novariska, F., Department of Pulmonology and Respiratory Medicine, University of Indonesia, Persahabatan Hospital, Jakarta, Indonesia; Wiyono, W.H., Department of Pulmonology and Respiratory Medicine, University of Indonesia, Persahabatan Hospital, Jakarta, Indonesia; Setiawati, A., Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Louisa, M., Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia
Objective: β 2 agonists have been used widely as relievers in asthma management. Procaterol is a selective β 2 agonist, claimed to be more selective than salbutamol. The present study aimed to compare the efficacy of nebulized procaterol with nebulized salbutamol in the treatment of moderate acute asthma. Methods: This was a randomized, double-blind, parallel group study in 140 patients with moderate acute asthma according to modified GINA 1998 who visited emergency department of Persahabatan Hospital, Jakarta. Patients were randomly assigned to receive three doses of either nebulized procaterol or salbutamol. The primary efficacy variable was the improvement in predicted peak expiratory flow rate (PEFR), while the secondary efficacy variable was the improvement in asthma score and the incidence and severity of adverse events. This study is registered at Current Controlled Trials, number ISCTRN25669625. Results: Baseline characteristics were similar in both groups. After treatment, there were significant improvement of % PEFR (p < 0.001) and asthma score (p < 0.001) in procaterol (n = 68) and salbutamol (n = 69) groups. It was shown that procaterol and salbutamol produced similar efficacy in improving % predicted PEFR and decreasing asthma score. Both treatments were well tolerated. Palpitation and sinus tachycardia were found as adverse events with low incidence. Conclusion: In moderate acute asthma, nebulized procaterol and nebulized salbutamol were both effective in improving PEFR and decreasing asthma score. Both treatments were well tolerated, adverse reactions were rare. ©2011 Dustri-Verlag Dr. K. Feistle.
Moderate acute asthma; Nebulized; Procaterol; Salbutamol
bronchodilating agent; corticosteroid; procaterol; salbutamol; adult; article; asthma; comparative study; controlled study; dose time effect relation; double blind procedure; drug efficacy; drug megadose; drug safety; drug tolerability; drug treatment failure; drug withdrawal; electrocardiogram; female; heart palpitation; human; incidence; major clinical study; male; nebulization; parallel design; peak expiratory flow; randomized controlled trial; scoring system; side effect; sinus tachycardia; Acute Disease; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Carbon Dioxide; Double-Blind Method; Female; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Oxygen; Peak Expiratory Flow Rate; Procaterol
09461965
ICTHE
21961486
Article
Q2